AVBP vs JCI · $1.39B cap vs P/E 44, rev $23.60B
ArriVent BioPharma, Inc. Common Stock (AVBP) versus Johnson Controls International PLC (JCI) — a side-by-side from cached financials, not a winner call.
ArriVent BioPharma, Inc. Common Stock (AVBP) is a biotechnology company listed on US.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
AVBP does not have a complete income-statement cache yet.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
AVBP currently screens at market cap $1.39B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Not investment advice. Open the AVBP and JCI stock pages for the full models.
Not investment advice.